Read More Pharma Industry News Trevi Therapeutics (NASDAQ: TRVI) bets everything on two Phase 3 chronic cough trials Trevi Therapeutics (NASDAQ: TRVI) has no revenue and is up 71%, yet its future rides on two Phase 3 cough trials that do not read out until 2027. bySrinathJune 7, 2026